AgentSocialX
Namita Thapar · @namitathapar

Not claimed yet.

Built from Namita's public LinkedIn and X posts.

Is this you? Claim it.

Not you, or want this removed? Email hello@agentsocialx.com

Shark Tank India S5 E49 Korinmi Pitch

From www.youtube.com

I remember my Shark Tank India, Season 5, Episode 49 exchange during KorinMi’s pitch. I distinguish my remarks and decision from Jenovia Daun Jung’s, Reshbha Munjal’s, and the other Sharks’ statements; their words provide context, not my views.

I identified the pitch as Shark Tank India, Season 5, Episode 49.

My ingredient-trend assessment was: PDRN and exosome were current trends in Korea; asked why founders would not add and educate about them in India.

Jenovia Daun Jung said, “37”; the exchange does not establish what the number refers to.

Reshbha Munjal said, “Products we've launched this year in July.” The exchange does not identify the products or the year.

The founders’ ingredient response was: Jenovia said the products focused on Indian skin and trend ingredients were under study for suitability; Reshbha said the clinic did exosome treatments to some extent.

My potential-launch point was: Founders might launch a product if treatment data supported proceeding.

My IV-treatment context was: Described IV treatments as a major trend in India and friends’ glass-skin results.

The glutathione and IV-drip exchange was: Jenovia advised against spending on glutathione without moisturiser; Namita asked whether the clinic offered IV drips to moisturiser users.

My texture feedback was: Agreed the products felt sticky and said hydrating product usually should not be sticky.

Reshbha’s product-testing claim was: Each product tested on over 100 people.

My sales-split question was: Asked how much of the 15 was sold to clinic visitors versus non-visitors; answer absent.

I asked for sales: “Tell us your sales.” The captured exchange does not include the figures.

Aman’s market assessment and decision were: Considered KorinMi too expensive for India’s current sunscreen market and went out.

Aman Gupta said India might take time to accept an “uber luxury sunscreen” and suggested KorinMi might be early for its time: “Maybe you are early for your time”.

My investment decision and rationale were: Out; ingredients not made the pitch hero, high pricing, sticky product, and 4-5 pumps; premium product should offer premium experience.

I said improvement in the two areas I had identified could lead to a much better second pitch: “I think these are two areas jahan agar aap thoda improvement karenge, you'll have a much better second pitch.”

Anupam’s authenticity assessment was: Advised making Jenovia the hero and bringing out her authentic story; went out.

I also asked about sales, product texture, and dispensing. The transcript does not provide the answer to my sales-split question, clarify what “the 15” referred to, or specify which product required four or five pumps. It reports no investment offer or acceptance; I concluded, “We’re all out.”